Compare Novavax Inc (NVAX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs TKO Group Holdings Inc — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while TKO Group Holdings Inc trades at $191.08 (market cap $13.97B). The key difference: TKO Group Holdings Inc is far larger — about 8.6× Novavax Inc's market cap, and TKO Group Holdings Inc pays a 1.65% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TKO | |
|---|---|---|
Market Cap | $1.62B | $13.97B |
Sector | Health | Technology |
52-Week High | $11.19 | $224.96 |
52-Week Low | $6.22 | $176.49 |
Enterprise Value | $1.20B | $18.33B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
TKO trades at $195.32, up 5.01% today, with a bullish technical outlook and strong analyst support. Recent Q2 2026 earnings showed revenue growth to $1.5 billion, though EPS missed expectations. The company benefits from media rights strength in UFC and WWE, with revenue projected to rise to $5.3 billion in 2026. Positive sentiment is driven by dividend declarations and conference participation.
The outlook is positive with a consensus price target of $228.17, implying 17% upside. Risks include earnings volatility and competitive pressures in sports entertainment. Institutional ownership trends and bullish analyst ratings (89% buy) support a favorable investment case, but investors should monitor execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
